April 4, 2024 – The Society for Clinical Research Sites (SCRS) is pleased to welcome Translational Drug Development (TD2) as an SCRS Global Impact Partner and Oncology Spirit Partner. TD2 is a leading provider of comprehensive preclinical drug development, translational and clinical trial services based in Scottsdale, Arizona.

SCRS Global Impact Partners (GIP) are comprised of industry sponsors, CROs, service providers, and site networks that are dedicated to supporting SCRS’ mission of ensuring site sustainability. GIP representatives participate in the development of SCRS events, advocacy initiatives, and educational content for research sites.

With TD2’s involvement as an Oncology Spirit Partner, the organization will contribute to the SCRS Oncology Program, creating site-focused resources for oncology research success. TD2 will also exhibit at the SCRS Oncology Site Solutions Summit on April 10-11, 2024, in Atlanta, Georgia. The Oncology Site Solutions Summit brings together research sites, sponsors, CROs, and solution providers to learn and share solutions for more efficient oncology research operations.

“We are thrilled to partner with SCRS in their important mission advocating for sites,” said Susan Night, Vice President of Site Engagement and Network Strategy for TD2. “It aligns perfectly with TD2’s commitment to building purposeful partnerships aimed at advancing science through clinical research with the goal of improving access to novel therapeutics and outcomes for patients.”

“Collaboration is a key ingredient to the future of precision medicine,” shared Sean Soth, SVP of Strategy and Global Business Partnerships for SCRS. “TD2 brings a unique approach and suite of services into our GIP community as a CRO focused on precision oncology. In many ways, our network can learn alongside TD2 about opportunities for sites and industry to collaborate,”  continued Soth. “SCRS Global Impact Partners are committed to addressing challenges faced by research sites today. As a leading precision oncology CRO, TD2 brings unparalleled expertise and resources to advance clinical research and drug development in the oncology space. By aligning our efforts, we can make substantial strides in ensuring sustainable cancer research and improving patient outcomes.”

For more information about the SCRS GIP program, visit scrsprograms.com.

About Translational Drug Development (TD2)

TD2 is a leader in precision oncology, providing innovative services for improved drug development. Using a dedicated, expert team with broad experience and understanding in cancer medicine, TD2 is uniquely positioned to support accelerated development of novel therapeutics. Rigorous and high-throughput translational preclinical development services, combined with regulatory affairs expertise, enables customized clinical trial design and execution. Our unique Oncology Ecosystem encourages the timely selection of patient populations who are most likely to benefit from a new agent, and the rapid identification of clinically significant endpoints. TD2 is committed to reducing the risks and uncertainty inherent in the drug development process with the ultimate goal of accelerating patient access to promising treatments. For more information, visit www.TD2inc.com.

About the Society for Clinical Research Sites (SCRS)

The Society for Clinical Research Sites (SCRS) is the leading advocacy organization dedicated to unifying the voice of the global clinical research site community. Representing more than 11,000 research sites in 54 countries, SCRS facilitates industry collaborations and conversations dedicated to site-focused advocacy, education, mentorship, and connection. SCRS is an active and influential champion for sites in industry initiatives to ensure that the perspective of sites is heard and valued. Learn more and get involved at myscrs.org. Our voice. Our community. Your success.